This is a working overview of thymalfasin, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-01. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
=== Grain-free and low-carbohydrate === Some dog food products differentiate themselves as grain- or carbohydrate-free to offer the consumer an alternative, claiming carbohydrates in pet foods to be fillers with little or no nutritional value. A study published in Nature suggests that domestic dogs' ability to easily metabolize carbohydrates may be a key difference between wolves and dogs. Some consumers and manufacturers say dogs perform better on grain-free diets, while some veterinarians doubt this for a lack of scientific evidence. In 2019, a study comparing dry dog food that was manufactured in the United States found that 75% of food containing feed grade grains also contained measurable levels of various mycotoxins (discussed below), while none of the grain-free dry diets tested had any detectable levels of mycotoxins. Feed grade (lower quality grade) grains that are allowed to spoil and become moldy are the suspected source of the mycotoxins. This is the first published study to show a potential health benefit to feeding grain-free commercial dry pet foods. In 2019, the U.S. Food and Drug Administration identified 16 dog food brands linked to canine heart disease. The FDA has investigated more than 500 cases of dilated cardiomyopathy (DCM) in dogs eating food marketed as grain-free. The 16 brands are: Acana, Zignature, Taste of the Wild, 4Health, Earthborn Holistic, Blue Buffalo, Nature's Domain, Fromm, Merrick, California Natural, Natural Balance, Orijen, Nature's Variety, NutriSource, Nutro, and Rachael Ray Nutrish.
=== Pharmacokinetics === N-Desalkylflurazepam has an elimination half-life of 47–150 hours (up to 200 hours in some healthy volunteers), with an average of ~71 hours. Peak blood concentrations of N-Desalkylflurazepam is reached at 10.2 h following a single 15 mg dose of Flurazepam, typically around ~10-20.4 ng/mL. Its plasma levels are unreliable amongst patients, and are largely influenced by liver disease, liver enzyme inducers and inhibitors, as well as old age (in men).
== Other animals == The thymus is present in all jawed vertebrates, where it undergoes the same shrinkage with age and plays the same immunological function as in other vertebrates. Recently, in 2011, a discrete thymus-like lympho-epithelial structure, termed the thymoid, was discovered in the gills of larval lampreys. Hagfish possess a protothymus associated with the pharyngeal velar muscles, which is responsible for a variety of immune responses. The thymus is also present in most other vertebrates, with structure and function similar to the human thymus. A second thymus in the neck has been reported sometimes to occur in the mouse. As in humans, the guinea pig's thymus naturally atrophies as the animal reaches adulthood, but the athymic hairless guinea pig (which arose from a spontaneous laboratory mutation) possesses no thymic tissue whatsoever, and the organ cavity is replaced with cystic spaces.
A number of European countries prescribe heroin for treatment of heroin addiction. The initial Swiss HAT (heroin-assisted treatment) trial ("PROVE" study) was conducted as a prospective cohort study with some 1,000 participants in 18 treatment centers between 1994 and 1996. At the end of 2004, 1,200 patients were enrolled in HAT in 23 treatment centers across Switzerland. Diamorphine may be used as a maintenance drug to assist the treatment of opiate addiction, normally in long-term chronic intravenous (IV) heroin users. It is only prescribed following exhaustive efforts at treatment via other means. It is sometimes thought that heroin users can walk into a clinic and walk out with a prescription, but the process takes many weeks before a prescription for diamorphine is issued. Though this is somewhat controversial among proponents of a zero-tolerance drug policy, it has proven superior to methadone in improving the social and health situations of addicts. The UK Department of Health's Rolleston Committee Report in 1926 established the British approach to diamorphine prescription to users, which was maintained for the next 40 years: dealers were prosecuted, but doctors could prescribe diamorphine to users when withdrawing. In 1964, the Brain Committee recommended that only selected approved doctors working at approved specialized centres be allowed to prescribe diamorphine and cocaine to users. The law was made more restrictive in 1968.
Sources: en.wikipedia.org
== Medical use == A 2018 Cochrane review found that fluphenazine was an imperfect treatment and other inexpensive drugs less associated with side effects may be an equally effective choice for people with schizophrenia. Another 2018 Cochrane review found that there was limited evidence that newer atypical antipsychotics were more tolerable than fluphenazine. Intramuscular depot injection forms are available as both the decanoate and enanthate esters.
Additionally, enobosarm fully maintained or restored levator ani weight at doses that did not affect LH or FSH levels in gonadally intact animals (≤0.1 mg/day). As such, it was more potent in stimulating muscle than testosterone at doses that did not affect gonadotropin levels. In gonadally intact male rats, enobosarm significantly increased levator ani muscle weight to 131% of intact controls but significantly decreased the weights of the prostate gland and seminal vesicles, demonstrating an antagonistic or partially agonistic effect in these tissues. In another animal study, enobosarm and DHT increased levator ani weights to similar or slightly different extents in intact male rats, but DHT strongly increased prostate weight while enobosarm reduced prostate weight. Aside from effects in muscle tissue, enobosarm has been assessed and found to completely maintain bone quality and composition in castrated male rats and to partially but not fully prevent bone loss in ovariectomized female rats, indicating potent anabolic effects in bone as well. In a phase 2 human clinical trial in healthy elderly men and postmenopausal women, enobosarm dose-dependently increased lean body mass (muscle mass) across doses of 0.1, 0.3, 1, and 3 mg/day, with a significant 1.3 kg gain over placebo at 3 mg/day and a non-significant 0.7 kg gain over placebo at 1 mg/day. Similarly, in two phase 3 clinical trials in men and postmenopausal women with muscle wasting due to non-small-cell lung cancer, enobosarm at 3 mg/day significantly increased lean body mass by 0.41 kg and 0.47 kg.
The aforementioned hydrodynamic and hydrostatic instruments may be employed in a variety of ways, or modes of operation, in order to address the particular separation needs of the scientist. Many modes of operation have been devised to take advantage of the strengths and potentialities of the countercurrent chromatography technique. Generally, the following modes may be performed with commercially available instruments.
Many Moroccan traffickers have anonymously stated that the trafficking operations at the Port of Antwerp would be impressively easy to execute for young people from neighbourhoods in Antwerp and Amsterdam. The traffickers often make corrupt deals with police officers to keep the trafficking of drugs run smoothly in exchange for large sums of money.
== Functions == Endorphins play a major role in the body's inhibitory response to pain. Research has demonstrated that meditation by trained individuals can be used to trigger endorphin release. Laughter may also stimulate endorphin production and elevate one's pain threshold. Endorphin production can be triggered by vigorous aerobic exercise. The release of β-endorphin has been postulated to contribute to the phenomenon known as "runner's high". However, experimental blockade of the mu opioid receptor has shown that endorphins are not strictly necessary for the development of exercise-induced euphoria. It has been suggested that other neurotransmitters, namely endocannabinoids, are more likely contributors. Endorphins may partially mediate exercise-induced analgesia.
Sources: en.wikipedia.org
Based on the size and histological staining characteristics of the fibrils, it is likely that at least in part they are composed of type III collagen (reticulin). An in vitro study with native collagen demonstrated that fibronectin binds to type III collagen rather than other types.
=== Youth levels === Townsend represented England at under-16, under-17 and under-19 level. He played three times for the under-16s between 2006 and 2007, making his debut in a 1–1 draw away with Wales on 20 October 2006 and his last appearance in a 2–0 away loss to Germany in April 2007. He scored twice on his under-17 debut, in a 6–1 win over Northern Ireland in August 2007, and went on to make six appearances, the last in a 0–0 draw with Portugal on 5 February 2008. Townsend's first two appearances at under-19 level came in the group stage of the 2009 European Championship; he was an unused substitute in the final, which England lost to Ukraine. He played four times in 2010, once as a starter in a friendly, and three times as a substitute in qualifiers for the 2010 competition. Townsend received his first call up to the England under-21 team in October 2012 for the Euro 2013 play-off matches against Serbia. He made his debut in the first leg as a 65th-minute substitute for Liverpool's Raheem Sterling. He also played in two U21 friendlies, in 2012 and 2013. In May 2013, Townsend was charged by The Football Association over alleged breaches of its rules on betting. He subsequently voluntarily withdrew from England's squad for the upcoming European Under-21 Championship finals. He later admitted to charges under the FA's rules for breaching football betting regulations. After a personal hearing, he was fined £18,000 and suspended for four months backdated to 23 May, with three months suspended until 1 July 2016.
==== Type III ==== Collagen quantity is sufficient, but is not of a high enough quality. Clinical differentiation between types III and IV is not always simple, and is further confounded by the fact that an untreated adult with type IV may have worse symptoms than a treated adult with type III; features only found in type III are its progressively deforming nature and the presence of a face with a "triangular" appearance. Another differentiating factor between type III and IV is blue sclerae; in type III, infants commonly have blue sclerae that gradually turn white with age, but blue sclerae are not commonly seen in type IV, although they are seen in 10% of cases. OI type III causes osteopenic bones that fracture very easily, sometimes even in utero, often leading to hundreds of fractures during a lifetime; early scoliosis that progresses until puberty; dwarfism (a final adult height frequently less than 4 feet or 120 centimetres); loose joints; and possible respiratory problems due to low rib cage volume causing low lung volumes. Due to the severity of the issues with the bones, neurological and seizure disorders are more likely to develop in type III. Basilar invagination, which puts pressure on the brainstem, may cause or contribute to early death; surgical treatment of it is more complex in OI cases.
== External links == Video: Hide & Animal Protein Glue: How to Select, Make & Use Video on hide glue, by Keith Cruickshank Old Brown Glue - Articles Why Not Period Glue? - article by W. Patrick Edwards on hide glue WPatrickEdwards: Why Use Reversible Glue?
In July 2020, the studio announced it was working on a new game. The Chinese Room revealed their new game, Still Wakes the Deep, at the Xbox Games Showcase 2023. On 17 July 2023, following the announcement of their new game, co-founder and creative director Dan Pinchbeck announced his departure from the studio after 15 years. At their PAX West panel, Paradox Interactive revealed that the Chinese Room had taken over development duties on Vampire: The Masquerade – Bloodlines 2 from Hardsuit Labs, who were fired from the project in 2021.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.